Oncology Institute (TOI) CEO has shares sold to cover RSU taxes

Rhea-AI Filing Summary

Oncology Institute, Inc. Chief Executive Officer Daniel Virnich reported an administrative stock transaction linked to restricted stock unit (RSU) vesting. On March 17, 2026, the issuer executed a sale of 11,834 shares of common stock at $3.59 per share to cover tax liabilities from the RSU vesting. Following this tax-related sale, Virnich’s directly held position is 1,788,150 common shares, indicating he retains a large equity stake after the routine transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Virnich Daniel

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Other	Common Stock	11,834	$3.59	$42K

Holdings After Transaction: Common Stock — 1,788,150 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Virnich Daniel

(Last) (First) (Middle)

C/O THE ONCOLOGY INSTITUTE INC.

18000 STUDEBAKER RD, SUITE 800

(Street)

CERRITOS CALIFORNIA 90703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		J(1)		11,834	D	$3.59	1,788,150	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award on March 17, 2026.

	/s/ Mark Hueppelsheuser, Attorney-in-Fact for Daniel Virnich	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Oncology Institute (TOI) report for its CEO?

Oncology Institute reported a routine insider transaction by CEO Daniel Virnich. The issuer sold 11,834 common shares on March 17, 2026 to cover tax liabilities from an RSU vesting, a standard administrative step rather than a discretionary open-market trade.

How many Oncology Institute (TOI) shares were sold to cover CEO RSU taxes?

The filing shows 11,834 common shares were sold at $3.59 each. According to the footnote, the issuer executed this sale specifically to satisfy tax liabilities triggered by the vesting of a restricted stock unit award on March 17, 2026.

Does the Oncology Institute CEO still hold a large stake after this Form 4?

Yes. After the tax-related sale, CEO Daniel Virnich directly holds 1,788,150 Oncology Institute common shares. This indicates the reported transaction is small compared with his overall position and reflects routine tax handling tied to RSU compensation rather than a major ownership change.

Was the Oncology Institute CEO’s Form 4 transaction a discretionary sale?

The transaction appears non-discretionary. A footnote states the issuer executed the sale to cover tax liabilities from RSU vesting on March 17, 2026, indicating it was a tax-management step connected to equity compensation, not an independent decision to reduce share exposure.

What does transaction code J mean in the Oncology Institute CEO Form 4?

Transaction code J represents “other acquisition or disposition” of non-derivative securities. In this case, a footnote clarifies the code reflects shares sold by the issuer to pay taxes owed on an RSU vesting, classifying it as an administrative restructuring-type event.

Is the Oncology Institute (TOI) CEO’s Form 4 likely a strong trading signal?

This Form 4 is a weak trading signal. The 11,834 shares were sold by the issuer to cover RSU-related taxes, and the CEO still directly holds 1,788,150 shares. Such tax-driven transactions are common in equity compensation programs and usually viewed as routine housekeeping.